Becton, Dickinson and Company (BDX) Q4 FY25 earnings call

Becton, Dickinson and Company delivered solid Q4 FY25 results, with strong underlying performance and record full-year adjusted EPS, driven by BD Excellence. The company is taking decisive strategic actions, including sales force expansion and cost optimization, to navigate specific macro headwinds in vaccines, China, and Alaris, while maintaining confidence in its long-term mid-single-digit growth profile and continued margin expansion for the New BD.